Please login to the form below

Not currently logged in
Email:
Password:

Prevail Therapeutics adds to its board of directors

Francois Nader joins the biotech

Francois NaderPrevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader.

From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn.

Nader said: “I am honoured to join the board of Prevail Therapeutics.

“The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help accelerate important therapeutic advances for patients with these devastating illnesses.”

Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America leadership team of Aventis and its predecessor companies, holding a number of executive positions including senior vice president of integrated healthcare markets.

Commenting on the appointments, Asa Abeliovich, founder and chief executive officer at Prevail, said: “Francois’ leadership and proven track record in building and operating biotech companies will be invaluable as we advance our pipeline of gene therapy programmes toward the clinic.”

31st May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics